On Wednesday, Mizuho (NYSE:MFG) Securities commenced coverage on shares of Doximity Inc (NYSE:NYSE:DOCS) with a Neutral rating, accompanied by a price target of $55.00. The firm acknowledges Doximity's recent growth resurgence in the fiscal year 2025, which has contributed to an impressive year-to-date (YTD) stock increase of 89%, outpacing the S&P 500's 27% rise over the same period.
The firm's revenue and earnings per share (EPS) estimates for Doximity are positioned above the consensus for the fiscal years 2025 to 2027.
Mizuho's outlook is based on the company's performance thus far in the fiscal year 2025, which has seen a notable resurgence in growth for Doximity.However, despite the positive growth trajectory and the firm's confidence in Doximity's future performance, Mizuho cautions that potential investors may find more favorable moments to invest in Doximity's stock. The caution stems from the ongoing quarterly volatility and the significant increase in the stock's value year-to-date.
This aligns with InvestingPro's Fair Value analysis, which suggests the stock is currently trading above its intrinsic value, with a P/E ratio of 57.68 reflecting premium pricing. This aligns with InvestingPro's Fair Value analysis, which suggests the stock is currently trading above its intrinsic value, with a P/E ratio of 57.68 reflecting premium pricing.
The firm's revenue and earnings per share (EPS) estimates for Doximity are positioned above the consensus for the fiscal years 2025 to 2027. Mizuho's outlook is based on the company's performance thus far in the fiscal year 2025, which has seen a notable resurgence in growth for Doximity.
However, despite the positive growth trajectory and the firm's confidence in Doximity's future performance, Mizuho cautions that potential investors may find more favorable moments to invest in Doximity's stock. The caution stems from the ongoing quarterly volatility and the significant increase in the stock's value year-to-date.
In other recent news, Doximity, a digital platform for medical professionals, has been the subject of several analyst reviews.
JPMorgan raised its price target for Doximity to $48 while maintaining a Neutral rating, citing the company's solid financial fundamentals despite a challenging macroeconomic environment. Similarly, Goldman Sachs initiated coverage on Doximity with a Neutral rating and a 12-month price target of $58, highlighting the company's steady performance.
In contrast, Morgan Stanley (NYSE:MS) upgraded Doximity from Underweight to Equalweight, setting a new price target of $53, despite concerns about a stretched valuation. Canaccord Genuity downgraded Doximity from Buy to Hold, raising the price target to $60, suggesting that the market's high growth expectations are now factored into the stock's valuation.
In terms of financial performance, Doximity reported robust Q2 FY25 results, with revenues reaching $137 million, a 20% increase year over year. The company also reported a record adjusted EBITDA margin of 56%, translating to $76 million, a 41% increase from the previous year.
In addition to these financial developments, Doximity introduced a new client portal, now used by over 40% of pharma clients, with full rollout expected in early 2025. For the third quarter, Doximity projects revenue to be between $152 million and $153 million, with adjusted EBITDA estimated at $83 million to $84 million.
Despite anticipating Q4 revenue challenges and increased operational expenses, the company has raised its full-year revenue guidance to between $535 million and $540 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.